myMPNteam

Yes! There are several non-chemotherapy treatment options for MPNs. Here's a quick overview:

Kinase Inhibitors (targeted therapies)
- Ruxolitinib (Jakafi) — commonly used for myelofibrosis and PV
- Fedratinib (Inrebic) — approved for myelofibrosis
- Pacritinib (Vonjo) — FDA approved in 2022 for myelofibrosis

Interferon Show Full Answer

Yes! There are several non-chemotherapy treatment options for MPNs. Here's a quick overview:

Kinase Inhibitors (targeted therapies)
- Ruxolitinib (Jakafi) — commonly used for myelofibrosis and PV
- Fedratinib (Inrebic) — approved for myelofibrosis
- Pacritinib (Vonjo) — FDA approved in 2022 for myelofibrosis

Interferon Therapies
These are lab-made versions of proteins your body naturally produces. They help control blood cell production and are used for PV and ET.

Anagrelide (Agrylin)
This is used to help lower platelet counts, particularly in ET.

Aspirin
For lower-risk PV and ET patients, aspirin combined with monitoring may be all that's needed. It's worth noting that the right treatment really depends on your specific MPN type, risk level, and symptoms. Your health care team is the best guide for figuring out which option fits your situation best.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

What Is a JAK2 Mutation?

What Is Cytoreductive Therapy in MPNs?